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Objective. Factors linked with insulin resistance were examined for their association with large-for-gestational-age (LGA) infant
birth weight and gestational diabetes. Study Design. Data came from a longitudinal cohort study of 2,305 subjects without overt
diabetes, analyzed using multinomial logistic and linear regression. Results. High maternal BMI (OR = 1.53 (1.11, 2.12)), height (1.98
(1.62, 2.42)), antidepressant use (1.71 (1.20, 2.44)), pregnancy weight-gain exceeding 40 pounds (1.79 (1.25, 2.57)), and high blood
sugar (2.68, (1.53, 5.27)) were all positively associated with LGA birth. Strikingly, the difference in risk from diagnosed and treated
gestational diabetes compared to women with a single abnormal glucose tolerance test (but no diagnosis of gestational diabetes)
was significant (OR = 0.65, 𝑝 = 0.12 versus OR = 2.84, 𝑝 < 0.01). When weight/length ratio was used instead, different factors were
found to be significant. BMI and pregnancy weight-gain were found to influence the development of gestational diabetes, through an
additive interaction. Conclusions. High prepregnancy BM, height, antidepressant use, pregnancy weight-gain exceeding 40 pounds,
and high blood sugar were associated with LGA birth, but not necessarily infant weight/length ratio. An additive interaction between
BMI and pregnancy weight-gain influenced gestational diabetes development.

1. Introduction
Normal pregnancy is characterized by a progressive increase
in insulin resistance, despite only minor decreases in glucose
tolerance. Pregnancy alters the maternal metabolic profile
away from the normal preference for glucose as an energy
source and towards the use of fatty acids, conserving glucose
and amino acids for the growing fetus. These metabolic
alterations enable the growing fetus to develop without
compromising maternal health. The impact of maternal diet
on the development of insulin resistance in pregnancy is
not fully understood, and has yielded mixed findings [1].

Investigation into the impact of diet on insulin resistance
in type 1 or 2 diabetes has found that certain nutritional
components, including Vitamin D, omega-3 fatty acids, total
dietary kilocalories, and macronutrient proportions, can
influence glucose homeostasis [2–5].
In the face of chronic underlying abnormalities in the
maternal metabolism, which may be exacerbated by overweight or obesity, these pregnancy-related changes can result
in pregnancy complications, including gestational diabetes
and abnormal fetal growth. Excess fetal growth is the most
common outcome of maternal insulin resistance [6]. Maternal obesity likely acts through pathways both related to and
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independent of insulin resistance to influence fetal growth.
Both obesity and gestational diabetes, however, add individually to the risk of excess fetal growth [7–11]. Excess fetal
growth is commonly measured using large-for-gestationalage (LGA), which is a birth weight at or above the 90th
percentile for population standardized birth weight. LGA
infants born to mothers with gestational diabetes have more
fat mass than LGA infants born to nondiabetic mothers, with
a direct correlation between infant fat mass and maternal
fasting glucose levels [12, 13]. The risk of developing gestational diabetes is higher in obese women than in women
of normal weight. After gestational diabetes develops, the
level of glycemic control achieved determines the level of risk
for excess fetal growth [14]. Poor glycemic control during
pregnancies complicated by gestational diabetes is more likely
to result in a LGA infant than those with good glycemic
control [8, 12, 14, 15].
Size-for-gestational-age is a widely used categorization
for fetal growth with definite advantages, including the
corrections for infant sex, infant gestational age, and normal
population birth weights [16]. However, the cut-points are
based on statistical considerations, which results in the
LGA and small-for-gestational-age (SGA) categories being
composed of both constitutionally and pathologically large
and small infants [17]. Recent research has shown that sizefor-gestational-age does not accurately reflect the adiposity
of newborns, but instead that weight/length has a stronger
correlation with infant body fat [17–20]. Maternal glucose
levels have been strongly linked to not just excess fetal growth,
but also excess fetal adiposity [21].
Strategies which reduce the incidence of LGA birth would
have implications for the health care system, the health of
the mother and the health of the child. The delivery of a
LGA infant requires a caesarean section more often than with
smaller infants [22], which, in turn, requires a longer hospital
stay and is more costly to the health care system [23]. Also,
vaginally delivered LGA infants tend to experience shoulder
dystocia more often than smaller infants, which also requires
more medical attention [22, 24]. There are also longer-term
health implications for children born with excess adiposity,
including metabolic abnormalities such as obesity and overt
diabetes [25–27].
In this study we examined how factors known to influence
insulin resistance, such as overweight and obesity, gestational
diabetes, diet and pregnancy weight gain, affect fetal growth.
Initially, fetal growth was categorized according to sizefor-gestational-age, with LGA status being the outcome of
interest. Secondarily, multivariable analyses were repeated
using the ratio of weight/length and the results compared.

2. Materials and Methods
Data for this study came from the Prenatal Health Project
(PHP), which is a longitudinal, population based cohort
of women with singleton pregnancies recruited in London,
Ontario, Canada, between 2002 and 2005. This study was
approved by The University of Western Ontario Review
Board for Health Sciences Research Involving Human Subjects and informed consent was obtained from all participants
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prior to their enrolment in the study. Details of the study sample have been reported elsewhere [28]. Briefly, a populationbased sample of women was recruited between 10–22 weeks
gestation from ultrasound clinics in the London, Ontario
area. Study participants resided in London, Ontario, and
spoke English well enough to provide informed consent. Data
was collected by survey on baseline sociodemographic factors, psychosocial stress, prepregnancy and early pregnancy
health and nutrition, and supplemented with information
extracted perinatally from maternal and newborn hospital
charts. For this analysis, women from the PHP cohort were
excluded if they had overt diabetes (type 1 or type 2), if they
reported using Metformin [29], or if they had missing data
for infant sex or birth weight.
2.1. Conceptualization and Measurement of Key Variables.
Fetal growth was represented by size-for-gestational-age
(small for gestational age (SGA), appropriate-for-gestationalage (AGA), and LGA; resp., birthweight <10th, 10th–90th,
and >90th percentile for gestational age) based on published
Canadian standards [16]. Newborn weight to length ratio
was used as a proxy for fetal adiposity as is common in the
literature.
Key independent variables included factors known to
influence insulin resistance: maternal overweight or obesity
(body mass index (BMI) of 25.0–29.9 and 30.0+ kg/m2 ),
gestational diabetes, diet and pregnancy weight gain. BMI
was calculated from self-reported prepregnancy height and
weight. Gestational diabetes (a clinical diagnosis based on
2 or more abnormal glucose tolerance tests) and abnormal
glucose tolerance (a single recorded abnormal test without a
gestational diabetes diagnosis) were abstracted from hospital
charts. Dietary factors considered included energy intake
(kilocalories), percentage of total energy that came from
fat, Vitamin D sufficiency and grams of omega-3 fatty acid
consumed daily. Dietary variables were captured from a
validated food frequency questionnaire (FFQ), which was
analyzed using the CANDAT Nutrient Analysis System
(Godin London, Inc., 2003) to determine participant’s average daily intakes. Nutritional data were excluded from the
analysis if energy intake was more than 2 standard deviations
from the mean for the cohort. Vitamin D sufficiency and
grams of omega-3 fatty acid consumed included both dietary
consumption and supplement use. Vitamin D sufficiency
was defined as meeting Health Canada’s recommendations
of 5 micrograms per day [30]. Average percentage of total
kilocalories from fat consumed per day was calculated relative
to the percentage of kilocalories from protein and carbohydrates. The percentage of kilocalories from fat was chosen
as a proxy for all three proportions (fat, carbohydrates and
protein), as they were interrelated and only one could be
included in the model to maintain statistical independence.
This choice was made on theoretical grounds and is unlikely
to affect the results. Pregnancy weight gain was available as
a categorical marker captured by a pregnancy risk scoring
system in hospital and extracted from women’s medical
records. This marker was recorded on maternal charts in a
risk scoring system in which women in labour were identified
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Table 1: Frequency and order of variable entry in blocks.
Variables entered in block 1 (prepregnancy factors)
Categorical
Prepregnancy BMI

Preexisting CVD or hypertension
Prepregnancy smoking
Parity

Income

Education
Continuous
Age (years)
Height (cm)
Variables entered in block 2 (early pregnancy factors)
Categorical
Antidepressant use
Depression
Smoking during pregnancy
Hyper emesis
Exercise
Continuous
Stress (standardized composite score)
Variables entered in block 3 (diet and nutrition)
Categorical
Vitamin D sufficiency
Continuous
Total kilocalories
Percentage of total kilocalories from fat
Grams of omega-3 fatty acid
Variables entered in block 4 (late pregnancy factors)
Categorical
Pregnancy weight gain

<18.5
18.5–24.9
25.0–29.9
30.0+
Yes
No
Yes
No
0
1+
<$30,000
$30,000–$79,999
$80,000
Did not complete high school
Completed high school only
Some education beyond high school
𝑛
2305
2289

Frequency (%)
99 (4%)
1350 (61%)
483 (22%)
282 (13%)
72 (3%)
2233 (97%)
525 (23%)
1767 (77%)
819 (36%)
1485 (64%)
262 (12%)
1096 (50%)
826 (38%)
119 (12%)
826 (38%)
1096 (50%)
Mean (±SD)
30 (±5)
165 (±7)

Yes
No
≥16 on CES-D (depressed)
<16 on CES-D
Yes
No
Yes
No
<3 times a week
≥3 times a week
𝑛
2296

Frequency (%)
38 (2%)
2267 (98%)
424 (19%)
1864 (81%)
234 (10%)
2060 (90%)
389 (17%)
1899 (83%)
766 (33%)
1539 (67%)
Mean (±SD)
0 (±1)

Yes
No
𝑛
2298
2298
2294

Frequency (%)
1938 (84%)
367 (16%)
Mean (±SD)
2028 (±746)
29 (±4)
0.16 (±0.22)

Insufficient
Appropriate
Excess

Frequency (%)
89 (4%)
1932 (84%)
284 (12%)

4

Journal of Diabetes Research
Table 1: Continued.

Gestational diabetes

Insulin use

None
Abnormal glucose tolerance
Gestational diabetes
Yes
No

as having high (at or above 40 lbs) or low weight gain (at or
below 20 lbs).
Potentially confounding variables included in the analysis
included: maternal age, smoking status (before and during
pregnancy), stress (a composite scale encompassing financial,
family, psychosocial and caregiver strain [31–33]), depression
(CES-D [34]), exercise during pregnancy, medication use,
nausea/vomiting during pregnancy, and a history of heart
disease or high blood pressure.
2.2. Statistical Analysis. The main data analyses were done
using Statistical Analysis Software (SAS) 9.1. Initially, frequencies for each independent variable and a univariable
examination of their relationship with size-for-gestational age
were completed. Multivariable analyses of factors associated
with fetal growth employed multinomial logistic regression
to identify associations with the three levels of size-forgestational-age, using AGA infants as the reference group,
allowing for the simultaneous calculation of odds ratios for
LGA and SGA. Multivariable analyses of factors associated
with newborn weight/length ratio employed linear regression.
Variables with univariate 𝑝 values of 𝑝 ≤ 0.20 were
entered into the model in blocks, in a temporal sequence
based on the point in the pregnancy where they were
measured to account for hypothesized mediation along the
causal pathway. During the model building process, variables
were retained if they achieved 𝑝 values of 𝑝 ≤ 0.20. For
the final model, this was adjusted to 𝑝 = 0.05. The specific
variables included in each block, as well as their order, are
presented in Table 1.
Three mediation pathways were hypothesized: gestational
diabetes mediating the association between BMI and a
LGA infant; gestational diabetes mediating the association
between diet early in pregnancy and a LGA infant; and early
pregnancy diet mediating the association between BMI and
a LGA infant. Early pregnancy diet included four dietary
variables: average kilocalories consumed per day, average
percentage of kilocalories from fat per day, total grams
of omega-3 fatty acid, and the sufficiency of Vitamin D
consumption. The Baron and Kenny36 criteria were used to
test for the presence of the hypothesized mediation.

3. Results
There were 3,656 women approached by recruiters for the
PHP, 2,747 of which agreed to participate in the study. Of
those women, 2,421 completed the prenatal survey and 2,409

2206 (95%)
26 (1%)
73 (3%)
36 (2%)
2269 (89%)

had chart data available. Gestational age and birth data were
abstracted for 2,383, of which 26 were duplicate participants
who were recruited in two different pregnancies. For the
26, one of the pregnancies was randomly selected and the
other deleted to preserve statistical independence of the
study sample. Of the 2,357 women in the final PHP cohort,
this analysis excluded 27 with overt diabetes, 17 without
infant gender recorded, 6 without a birth weight, and 2 who
used Metformin during pregnancy without having diabetes.
There were 2,305 women who met the eligibility criteria for
this study. Table 1 presents the frequencies for independent
variables included in the analyses.
Table 2 presents the results of both univariable and multivariable logistic regression analyses for factors associated
with fetal growth. None of the hypothesized mediation was
found to be present in this cohort (results not shown).
Factors found to be associated with LGA in the final model
were prepregnancy BMI of 25.0–30.0 (OR = 1.34) or 30.0+
(OR = 1.54), height (OR = 1.94), antidepressant use (OR =
1.70), excess pregnancy weight gain (OR = 1.74), and glucose
intolerance below the threshold of gestational diabetes (OR =
2.84). It should be noted that, although the association with a
prepregnancy BMI of 25.0–30.0 was modest, there is evidence
of a dose-response relationship between prepregnancy BMI
and the odds of having a LGA infant. The odds ratios for each
variable did not change substantially with intermediate steps
in the model building indicating that there was no substantial
confounding present. Thus only the univariable and final
model results are included in Table 2.
Table 3 presents the results of multiple linear regression analyses of the factors contributing to higher infant
weight/length ratio. Prepregnancy obesity (30.0+), parity,
maternal height, excess pregnancy weight gain, and glucose
intolerance without gestational diabetes were significantly
associated with a higher infant weight/length ratio in this
model. Conversely, smoking during pregnancy and insufficient weight gain were associated with significantly lower
infant weight/length ratios in this model.

4. Discussion
4.1. Interpretation of Results. Prepregnancy BMI above 25.0,
height, antidepressant use, excess pregnancy weight gain,
and abnormal glucose intolerance are all associated with an
increased odds of delivering a LGA infant. Further, the odds
ratios associated with prepregnancy BMI, height, weight gain,
and abnormal glucose tolerance were comparable to other
studies reported in the literature [6, 8–11, 35–41].
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Table 2: Determinants of size for gestational age (LGA).
Odds ratio of LGA
(95% CI)
Prepregnancy BMI
<18.5
18.5–24.9 (ref)
25.0–30.0
30.0+
Age (per 1 year)
Preexisting CVD or hypertension
Yes
No (ref)
Prepregnancy smoking
Yes
No (ref)
Parity
0 (ref)
1+
Height (for each 10 cm change)
Education
Did not complete high school
Completed high school only
Education beyond high school (ref)
Income
<$30,000
$30,000–$80,000 (ref)
$80,000+
Stress
Antidepressant use
Yes
No (ref)
Depression
<16 on CES-D (ref)
≥16 on CES-D
Smoking during pregnancy
Yes
No (ref)
Hyper emesis
Yes
No (ref)
Exercise
≥3 times a week (ref)
<3 times a week
Total kilocalories (per 100 kcal)
Percent kcals from fat (per 10%)
Vitamin D sufficiency
Yes (ref)
No
Grams of omega-3 (per 1 gram)

Univariable

Final model

0.59 (0.33, 1.07)
—
1.37 (1.03, 1.81)
1.44 (1.05, 1.98)
1.01 (0.99, 1.04)

0.58 (0.32, 0.94)
—
1.34 (1.00, 1.79)
1.53 (1.11, 2.12)
—

1.01 (0.99, 1.04)
—

—

0.98 (0.84, 1.14)
—

—

—
1.11 (0.97, 1.26)
1.86 (1.54, 2.25)

—

0.91 (0.59, 1.38)
0.98 (0.70, 1.35)
—

1.98 (1.62, 2.42)
—

0.83 (0.62, 1.12)
—
0.96 (0.78, 1.19)
1.03 (0.91, 1.16)

—

1.85 (1.32, 2.60)
—

1.71 (1.20, 2.44)
—

—
0.97 (0.82, 1.14)

—

0.83 (0.65, 1.06)
—

—

0.87 (0.73, 1.03)
—

—

—
1.02 (0.89, 1.16)
1.01 (0.99, 1.02)
1.20 (0.89, 1.60)

—

—
0.95 (0.81, 1.13)
0.89 (0.50, 1.61)

—

—
—
—
—
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Table 2: Continued.
Odds ratio of LGA
(95% CI)

Weight gain
Insufficient
Appropriate (ref)
Excess
Gestational diabetes
None (ref)
Abnormal glucose tolerance
Gestational diabetes
Insulin use
Yes
No (ref)

Univariable

Final model

0.57 (0.32, 1.00)
—
1.77 (1.25, 2.49)

0.52 (0.29, 0.94)
—
1.79 (1.25, 2.57)

—
2.28 (1.29, 4.02)
0.80 (0.49, 1.30)

—
2.84 (1.53, 5.27)
0.65 (0.38, 1.12)

1.38 (0.93, 2.06)
—

—

*
Age, preexisting CVD or hypertension, prepregnancy smoking, parity, education, income, stress, depression, smoking during pregnancy, hyper emesis,
exercise, total kilocalories, percent kilocalories from fat, vitamin D sufficiency, omega-3 fatty acid consumption, and insulin use did not reach statistical
significance during the model building process.

Because taller maternal height reflects maternal early
childhood nutrition, and also has a strong genetic component, one might understand maternal height not as a risk
factor for the delivery of a LGA infant, but rather as a
unmodifiable covariate that is associated with the delivery of
a LGA infant partially due to its genetic component [42].
Treated gestational diabetes did not significantly contribute to the risk of delivering a LGA infant, but a single
abnormal glucose tolerance test during pregnancy, without a clinical diagnosis of gestational diabetes, did (OR
= 2.84, 𝑝 < 0.01). The contrast in these two measures
may illustrate the differences in risk between treated and
untreated glucose intolerance during pregnancy. Literature
on this topic is mixed but most studies seem to indicate that
gestational diabetes increases the risk of delivering a LGA
infant only when it is untreated [15]. Although we did not
measure blood glucose control, we speculate that the lack
of an association between treated gestational diabetes and
LGA in this data set may suggest good glycemic control
in those with diagnosed gestational diabetes. Women who
were not diagnosed with gestational diabetes but did have
a single documented abnormal glucose tolerance test may
have had poorer glucose control, reflected in the increased
odds of delivering a LGA infant. Our findings are consistent
with other research which found that degree of maternal
glycaemia had the highest correlation with birth size [6].
Our results show that even at blood glucose levels below
what is considered clinical gestational diabetes in Canada,
women are delivering a disproportionately high number of
LGA infants. These findings highlight the importance of
blood glucose control during pregnancy independently from
a clinical diagnosis for gestational diabetes.
Taking antidepressant medication was found to significantly increase the risk of delivering a LGA infant.
Recent literature has suggested that depression and obesity
are often comorbid conditions characterized by increased

inflammation due to the overactivity of immune cytokines
[43]. Inflammation has been shown to disrupt both the
hypothalamic-pituitary-adrenal (HPA) axis as well as some
neuroregulatory systems, both of which play a role in the
pathology of depression [44, 45]. In this way, antidepressant
use may be a marker for clinical depression in our population,
and its association with LGA infants may be further evidence
of this environment of increased inflammation and its impact
on glucose metabolism during pregnancy. We speculate
that this result may be evidence of a reduction in glucose
tolerance caused by the increased inflammation present due
to depression, and which then manifests as poorer glycemic
regulation during pregnancy and an increased risk of a LGA
infant.
Total kilocalories, the percentage of kilocalories from
fat, omega-3 fatty acid intake and Vitamin D consumption
did not affect a woman’s risk of delivering a LGA infant,
possibly due to a lack of precision in these measures, which
would bias the odds ratios towards the null value. Further
research is needed to determine if and how diet impacts
the risk of developing gestational diabetes and delivering a
LGA infant. The null results could also reflect confounding
by other factors with greater explanatory power and does
not necessarily indicate that diet does not contribute to
gestational diabetes and LGA.
We found that there was a difference in the risk factor
profile of infants who were large when classified by LGA,
compared to those that were large when classified using the
weight/length ratio. Our results suggest not only that the
factors contributing to increased infant weight/length ratio
may be subtly different from those contributing to LGA
status, but also that while these two measures are correlated,
they are distinctly different measures. This is important
given that LGA is used predominantly in the literature,
sometimes for questions that may be better represented
using a weight/length ratio. The differences in the risk factor
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Table 3: Determinants of fetal adiposity using weight/length ratio (linear regression).
Regression coefficients
(95% CI)
Prepregnancy BMI
<18.5
18.5–24.9 (ref)
25.0–30.0
30.0+
Age (per 1 year)
Preexisting CVD or hypertension
Yes
No (ref)
Prepregnancy smoking
Yes
No (ref)
Parity
0 (ref)
1+
Height (for each 10 cm change)
Education
Did not complete high school
Completed high school only
Education beyond high school (ref)
Income
<$30,000
$30,000–$80,000 (ref)
$80,000+
Stress
Antidepressant use
Yes
No (ref)
Depression
<16 on CES-D (ref)
≥16 on CES-D
Smoking during pregnancy
Yes
No (ref)
Hyper emesis
Yes
No (ref)
Exercise
≥3 times a week (ref)
<3 times a week
Total kilocalories (per 100 kcal)
Percentage of kcals from fat (per 10%)
Vitamin D sufficiency
Yes (ref)
No
Grams of omega-3 (per 1 gram)

Univariable

Final model

−1.72 (−3.88, 0.44)
—
0.42 (−0.64, 1.49)
0.98 (−0.32, 2.28)
0.13 (0.04, 0.21)

−1.52 (−3.63, 0.60)
—
0.38 (−0.67, 1.42)
1.35 (0.07, 2.64)
—

−0.87 (−3.22, 1.47)
—

—

−1.10 (−2.13, −0.06)
—

—

—
1.65 (0.76, 2.54)
2.17 (1.54, 2.79)

—
1.95 (1.07, 2.83)
2.12 (1.50, 2.74)

−0.89 (−2.81, 1.03)
−1.04 (−2.37, 0.30)
—

—

−0.01 (−1.41, 1.40)
—
0.27 (−0.65, 1.19)
−0.15 (−0.58, 0.27)

—

—

2.23 (−1.43, 5.88)
—

—

—
−0.92 (−2.03, 0.19)

—

−3.03 (−4.49, −1.56)
—

−3.01 (−4.45, −1.57)
—

−0.82 (−1.93, 0.29)
—

—

—
−0.04 (−0.94, 0.86)
0.005 (−0.05, 0.06)
0.54 (−0.44, 1.53)

—

—
−0.37 (−1.54, 0.80)
0.52 (−1.44, 2.49)

—
—
—
—
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Table 3: Continued.
Regression coefficients
(95% CI)

Weight gain
Insufficient
Appropriate (ref)
Excess
Gestational diabetes
None (ref)
Abnormal glucose tolerance
Gestational diabetes
Insulin use
Yes
No (ref)

Univariable

Final model

−2.16 (−4.30, −0.02)
—
2.01 (0.74, 3.27)

−2.42 (−4.54, −0.30)
—
2.15 (0.90, 3.40)

—
4.82 (1.09, 8.54)
−0.05 (−2.53, 2.44)

—
4.98 (1.34, 8.63)
0.03 (−2.42, 2.48)

0.49 (−2.69, 3.95)
—

—

*
Age, preexisting CVD or hypertension, prepregnancy smoking, parity, education, income, stress, antidepressant use, depression, hyper emesis, exercise, total
kilocalories, percent kilocalories from fat, vitamin D sufficiency, omega-3 fatty acid consumption, and insulin use did not reach statistical significance during
the model building process.

profile of LGA infants, compared to infants with a high
weight/length ratio, have important implications for future
work in this area.
4.2. Strengths and Limitations. The PHP cohort is a key
strength to this analysis, with its breadth of available data
and the widely generalizable population upon which it is
based. An additional strength is the use of a strong theoretical framework, based on biological mechanisms from the
literature and epidemiological studies, which was used to
guide and interpret the analysis and understand the complex
relationships that exist. The use of an analytic technique that
restricted the reference group to only AGA infants, instead of
incorporating all “non-LGA” infants, is also a strength.
There are also some limitations to this analysis. The
data used to calculate participant’s BMIs were self-reported.
Because prepregnancy weight was a major factor of interest in
this analysis, underestimating women’s weight would bias our
risk estimates associated with obesity towards the null. This
should be kept in mind when interpreting the results of this
study, even though it is a common limitation in the literature.
Additionally, weight gain was captured as categories of weight
gain instead of as the actual amount of weight gained during
pregnancy. As the Institute of Medicine [46] (IOM) and
Health Canada [47] both recommend different amounts of
weight gain during pregnancy depending on maternal BMI,
our weight gain categories may misclassify overweight and
obese women’s weight gain. If a woman had an overweight
prepregnancy BMI and gained 26 lbs during her pregnancy,
she would be classified as having gained excess weight by
the guidelines but would have been put into the category for
appropriate weight gain in this study. This is a limitation of
the data that was collected for this cohort but we believe that
it would bias our results towards the null for the excess weight
gain category, indicating that the effects seen here for weight

gain may actually be stronger if we had been able to take the
guidelines into account.
Also, our data for gestational diabetes and abnormal
glucose intolerance were not collected as discrete clinical
values, but instead as the presence or absence of the test
results in the patient’s chart. As with other studies, our nutritional data may be limited by participants reporting what they
thought they should be eating instead of accurately reporting
their nutritional consumption. This has been documented in
other studies [48] and may help to explain our null results for
the nutritional factors.

5. Conclusions
Prepregnancy obesity and excess pregnancy weight gain
both contribute to an increased risk of delivering an LGA
infant. This further supports the findings from other similar
studies in the literature and points to the need for future
research focusing on both individual-level and communitylevel strategies for managing obesity and pregnancy weight
gain, as both factors are modifiable, although modification is
not easily achieved.
Our study also illustrates that excess fetal growth and
excess fetal adiposity may not have the same determinants;
our results indicate that the same factors do not influence
both outcomes in the same way.
The most striking finding of this study is the difference
in LGA risk conferred by diagnosed and treated gestational
diabetes (OR = 0.65, 𝑝 = 0.12), compared to that from a single
abnormal glucose tolerance test without a diagnosis of gestational diabetes (OR = 2.84, 𝑝 < 0.01). This suggests that the
odds of delivering an LGA infant are lowered by “treated” gestational diabetes [49]. Our results highlight the importance
of diagnosis, but more importantly treatment as this seems to
be where the real benefit exists. Future research should focus
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on the establishment and adoption of universal screening
and diagnosis procedures for gestational diabetes. This is
already underway with work such as the recommendations
made by the such as the International Association of Diabetes
and Pregnancy Study Groups (IADPSG) which has made
recommendations for internationally recognized gestational
diabetes diagnosis criteria [6, 50].
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